Teva Pharma (TEVA) Reports In-Line Q1 EPS, Reaffirms Outlook

Teva Pharma (NYSE: TEVA) reported Q1 EPS of $1.06, in-line with the analyst estimate of $1.06. Revenue for the quarter came in at $5.6 billion versus the consensus estimate of $5.7 billion.

Dr. Peterburg continued, “Looking forward to the rest of 2017, we are reaffirming our full-year outlook. While we have several challenges facing us, including the U.S Generics market dynamics and greater instability in the Venezuela market, we are very confident that the global business we have built will allow Teva to thrive in the future as the leader in the generics industry. I would like to thank the employees of Teva for their hard work and dedication to continuing to deliver on our commitment to patients around the world.”

For earnings history and earnings-related data on Teva Pharma (TEVA) click here.

You May Also Be Interested In

• AbbVie updates 2026 EPS guidance after $291M IPR&D charge
• Piper Sandler defends Oracle ahead of earnings, sees $2.2 billion OCI upside
• Exyn Technologies reports Q1 2026 results after Nasdaq IPO